nach oben

Erschienen in:

06.11.2023 | Original Article

Non-viral pathogens of infectious diarrhoea post-allogeneic stem cell transplantation are associated with graft-versus-host disease

Erschienen in: Annals of Hematology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Infectious diarrhoea is common post-allogeneic haematopoietic stem-cell transplantation (alloHSCT). While the epidemiology of Clostridioides difficile infection (CDI) post-alloHSCT has been described, the impact of other diarrhoeal pathogens is uncertain. We reviewed all alloHSCT between 2017 and 2022 at a single large transplant centre; 374 patients were identified and included. The 1-year incidence of infectious diarrhoea was 23%, divided into viral (13/374, 3%), CDI (65/374, 17%) and other bacterial infections (16/374, 4%). There was a significant association between infectious diarrhoea within 1 year post-transplant and the occurrence of severe acute lower gastrointestinal graft-versus-host disease (GVHD, OR = 4.64, 95% CI 2.57–8.38, p < 0.001) and inferior GVHD-free, relapse-free survival on analysis adjusted for age, donor type, stem cell source and T-cell depletion (aHR = 1.64, 95% CI = 1.18–2.27, p = 0.003). When the classes of infectious diarrhoea were compared to no infection, bacterial (OR = 6.38, 95% CI 1.90–21.40, p = 0.003), CDI (OR = 3.80, 95% CI 1.91–7.53, p < 0.001) and multiple infections (OR = 11.16, 95% CI 2.84–43.92, p < 0.001) were all independently associated with a higher risk of severe GI GVHD. Conversely, viral infections were not (OR = 2.98, 95% CI 0.57–15.43, p = 0.20). Non-viral infectious diarrhoea is significantly associated with the development of GVHD. Research to examine whether the prevention of infectious diarrhoea via infection control measures or modulation of the microbiome reduces the incidence of GVHD is needed.

Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12):2462–2465CrossRefPubMed

Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J, Antin JH, Bolwell BJ, Bredeson C, Cahn J-Y, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T (2012) Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119(1):296–307. https://doi.org/10.1182/blood-2011-06-364265CrossRefPubMedPubMedCentral

El-Jawahri A, Li S, Antin JH, Spitzer TR, Armand PA, Koreth J, Nikiforow S, Ballen KK, Ho VT, Alyea EP, Dey BR, McAfee SL, Glotzbecker BE, Soiffer RJ, Cutler CS, Chen Y-B (2016) Improved treatment-related mortality and overall survival of patients with grade IV acute GVHD in the modern years. Biol Blood Marrow Transplant 22(5):910–918. https://doi.org/10.1016/j.bbmt.2015.12.024CrossRefPubMed

Weisdorf D, Zhang M-J, Arora M, Horowitz MM, Rizzo JD, Eapen M (2012) Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 18(11):1727–1733. https://doi.org/10.1016/j.bbmt.2012.06.014CrossRefPubMedPubMedCentral

Garnett C, Apperley JF, Pavlů J (2013) Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol 4(6):366–378. https://doi.org/10.1177/2040620713489842CrossRefPubMedPubMedCentral

Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringdén O (2008) Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 26(35):5728–5734. https://doi.org/10.1200/jco.2008.17.6545CrossRefPubMedPubMedCentral

Alonso CD, Treadway SB, Hanna DB, Huff CA, Neofytos D, Carroll KC, Marr KA (2012) Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 54(8):1053–1063. https://doi.org/10.1093/cid/cir1035CrossRefPubMedPubMedCentral

Van Praet JT, Huysman A, De Knijf E, De Buyser S, Snauwaert S, Van Droogenbroeck J, Lodewyck T, Schauwvlieghe A, Selleslag D, Reynders M (2023) Infectious diarrhea after allogeneic hematopoietic cell transplantation assessed by a multiplex polymerase chain reaction assay. Int J Infect Dis 127:17–22. https://doi.org/10.1016/j.ijid.2022.11.045CrossRefPubMed

Kelly CP, LaMont JT (2008) Clostridium difficile–more difficult than ever. N Engl J Med 359(18):1932–1940. https://doi.org/10.1056/NEJMra0707500CrossRefPubMed

10.

Slimings C, Armstrong P, Beckingham WD, Bull AL, Hall L, Kennedy KJ, Marquess J, McCann R, Menzies A, Mitchell BG, Richards MJ, Smollen PC, Tracey L, Wilkinson IJ, Wilson FL, Worth LJ, Riley TV (2014) Increasing incidence of Clostridium difficile infection, Australia, 2011–2012. Med J Aust 200(5):272–276. https://doi.org/10.5694/mja13.11153CrossRefPubMed

11.

Chung S, Abou Mourad Y (2019) Clostridium difficile infection among hematopoietic stem cell transplant recipients and subsequent development of graft-versus-host disease. Blood 134:4494. https://doi.org/10.1182/blood-2019-129663CrossRef

12.

Bhutani D, Jaiyeoba C, Kim S, Naylor P, Uberti JP, Ratanatharathorn V, Ayash L, Deol A, Alavi A, Revankar S, Chandrasekar P (2019) Relationship between clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant 54(1):164–167. https://doi.org/10.1038/s41409-018-0270-xCrossRefPubMed

13.

Chakrabarti S, Lees A, Jones SG, Milligan DW (2000) Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant 26(8):871–876. https://doi.org/10.1038/sj.bmt.1702627CrossRefPubMed

14.

Ramanathan M, Kim S, He N, Chen M, Hematti P, Abid MB, Rotz SJ, Williams KM, Lazarus HM, Wirk B, Yin DE, Kanakry CG, Perales M-A, Chemaly RF, Dandoy CE, Riches M, Ustun C (2023) The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant—a CIBMTR study. Bone Marrow Transplant 58(4):360–366. https://doi.org/10.1038/s41409-022-01896-zCrossRefPubMed

15.

De La Cochetière MF, Durand T, Lalande V, Petit JC, Potel G, Beaugerie L (2008) Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microb Ecol 56(3):395–402. https://doi.org/10.1007/s00248-007-9356-5CrossRefPubMed

16.

Sehgal K, Khanna S (2021) Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface. Therap Adv Gastroenterol 14:1756284821994736. https://doi.org/10.1177/1756284821994736CrossRefPubMedPubMedCentral

17.

Rea MC, O’Sullivan O, Shanahan F, O’Toole PW, Stanton C, Ross RP, Hill C (2012) Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 50(3):867–875. https://doi.org/10.1128/jcm.05176-11CrossRefPubMedPubMedCentral

18.

Nelson AM, Walk ST, Taube S, Taniuchi M, Houpt ER, Wobus CE, Young VB (2012) Disruption of the human gut microbiota following Norovirus infection. PLoS ONE 7(10):e48224. https://doi.org/10.1371/journal.pone.0048224CrossRefPubMedPubMedCentral

19.

Hoyt R, Ritchie DS, Roberts AW, Macgregor L, Curtis DJ, Szer J, Grigg AP (2008) Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. Bone Marrow Transplant 41(7):651–658. https://doi.org/10.1038/sj.bmt.1705955CrossRefPubMed

20.

Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18(4):295–304. https://doi.org/10.1097/00007890-197410000-00001CrossRefPubMed

21.

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME (2015) National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The (2014) Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21(3):389-401.e381. https://doi.org/10.1016/j.bbmt.2014.12.001CrossRef

22.

Yolken RH, Bishop CA, Townsend TR, Bolyard EA, Bartlett J, Santos GW, Saral R (1982) Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med 306(17):1009–1012. https://doi.org/10.1056/nejm198204293061701CrossRefPubMed

23.

Kelly CP (2012) Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 18(Suppl 6):21–27. https://doi.org/10.1111/1469-0691.12046CrossRefPubMed

24.

Ma GK, Brensinger CM, Wu Q, Lewis JD (2017) Increasing incidence of multiply recurrent clostridium difficile infection in the United States: a cohort study. Ann Intern Med 167(3):152–158. https://doi.org/10.7326/m16-2733CrossRefPubMed

25.

Kinnebrew MA, Lee YJ, Jenq RR, Lipuma L, Littmann ER, Gobourne A, No D, van den Brink M, Pamer EG, Taur Y (2014) Early Clostridium difficile infection during allogeneic hematopoietic stem cell transplantation. PLoS ONE 9(3):e90158. https://doi.org/10.1371/journal.pone.0090158CrossRefPubMedPubMedCentral

26.

Rogers WS, Westblade LF, Soave R, Jenkins SG, van Besien K, Singh HK, Walsh TJ, Small CB, Shore T, Crawford CV, Satlin MJ (2020) Impact of a multiplexed polymerase chain reaction panel on identifying diarrheal pathogens in hematopoietic cell transplant recipients. Clin Infect Dis 71(7):1693–1700. https://doi.org/10.1093/cid/ciz1068CrossRefPubMed

27.

Zeiser R (2019) Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol 187(5):563–572. https://doi.org/10.1111/bjh.16190CrossRefPubMed

28.

Zeiser R, Blazar BR (2017) Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med 377(22):2167–2179. https://doi.org/10.1056/NEJMra1609337CrossRefPubMedPubMedCentral

29.

Klämbt V, Wohlfeil SA, Schwab L, Hülsdünker J, Ayata K, Apostolova P, Schmitt-Graeff A, Dierbach H, Prinz G, Follo M, Prinz M, Idzko M, Zeiser R (2015) A novel function for P2Y2 in myeloid recipient-derived cells during graft-versus-host disease. J Immunol 195(12):5795–5804. https://doi.org/10.4049/jimmunol.1501357CrossRefPubMed

30.

Choi SW, Levine JE, Ferrara JL (2010) Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am 30(1):75–101. https://doi.org/10.1016/j.iac.2009.10.001CrossRefPubMedPubMedCentral

31.

Fredricks DN (2019) The gut microbiota and graft-versus-host disease. J Clin Investig 129(5):1808–1817. https://doi.org/10.1172/JCI125797CrossRefPubMedPubMedCentral

32.

Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y (2005) Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 5(6):1383–1391. https://doi.org/10.1111/j.1600-6143.2005.00844.xCrossRefPubMed

33.

Bekkum DWV, Roodenburg J, Heidt PJ, Waaij DVD (1974) Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. JNCI 52(2):401–404. https://doi.org/10.1093/jnci/52.2.401CrossRefPubMed

34.

Burgos da Silva M, Ponce DM, Dai A, M. Devlin S, Gomes ALC, Moore G, Slingerland J, Shouval R, Armijo GK, DeWolf S, Fei T, Clurman A, Fontana E, Amoretti LA, Wright RJ, Andrlova H, Miltiadous O, Perales M-A, Taur Y, Peled JU, van den Brink MRM (2022) Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease. Blood 140(22):2385–2397. https://doi.org/10.1182/blood.2021015352CrossRefPubMedPubMedCentral

35.

Taur Y, Jenq RR, Perales M-A, Littmann ER, Morjaria S, Ling L, No D, Gobourne A, Viale A, Dahi PB, Ponce DM, Barker JN, Giralt S, van den Brink M, Pamer EG (2014) The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124(7):1174–1182. https://doi.org/10.1182/blood-2014-02-554725CrossRefPubMedPubMedCentral

36.

Payen M, Nicolis I, Robin M, Michonneau D, Delannoye J, Mayeur C, Kapel N, Berçot B, Butel M-J, Le Goff J, Socié G, Rousseau C (2020) Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. Blood Adv 4(9):1824–1832. https://doi.org/10.1182/bloodadvances.2020001531CrossRefPubMedPubMedCentral

37.

DeFilipp Z, Hohmann E, Jenq RR, Chen YB (2019) Fecal microbiota transplantation: restoring the injured microbiome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 25(1):e17–e22. https://doi.org/10.1016/j.bbmt.2018.10.022CrossRefPubMed

38.

Vollaard EJ, Clasener HA (1994) Colonization resistance. Antimicrob Agents Chemother 38(3):409–414. https://doi.org/10.1128/aac.38.3.409CrossRefPubMedPubMedCentral

39.

Kamada N, Chen GY, Inohara N, Núñez G (2013) Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 14(7):685–690. https://doi.org/10.1038/ni.2608CrossRefPubMedPubMedCentral

40.

Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN, Garrett WS (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341(6145):569–573. https://doi.org/10.1126/science.1241165CrossRefPubMed

41.

Donohoe DR, Garge N, Zhang X, Sun W, O’Connell TM, Bunger MK, Bultman SJ (2011) The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 13(5):517–526. https://doi.org/10.1016/j.cmet.2011.02.018CrossRefPubMedPubMedCentral

42.

Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, Littmann ER, Ling L, Gobourne AC, Miller LC, Docampo MD, Peled JU, Arpaia N, Cross JR, Peets TK, Lumish MA, Shono Y, Dudakov JA, Poeck H, Hanash AM, Barker JN, Perales M-A, Giralt SA, Pamer EG, van den Brink MRM (2015) Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant 21(8):1373–1383. https://doi.org/10.1016/j.bbmt.2015.04.016CrossRefPubMedPubMedCentral

43.

Shono Y, van den Brink MRM (2018) Gut microbiota injury in allogeneic haematopoietic stem cell transplantation. Nat Rev Cancer 18(5):283–295. https://doi.org/10.1038/nrc.2018.10CrossRefPubMedPubMedCentral

44.

Bilinski J, Grzesiowski P, Sorensen N, Madry K, Muszynski J, Robak K, Wroblewska M, Dzieciatkowski T, Dulny G, Dwilewicz-Trojaczek J, Wiktor-Jedrzejczak W, Basak GW (2017) Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin Infect Dis 65(3):364–370. https://doi.org/10.1093/cid/cix252CrossRefPubMed

45.

Pession A, Zama D, Muratore E, Leardini D, Gori D, Guaraldi F, Prete A, Turroni S, Brigidi P, Masetti R (2021) Fecal microbiota transplantation in allogeneic hematopoietic stem cell transplantation recipients: a systematic review. J Pers Med 11 (2). https://doi.org/10.3390/jpm11020100

46.

van Lier YF, Davids M, Haverkate NJE, de Groot PF, Donker ML, Meijer E, Heubel-Moenen FCJI, Nur E, Zeerleder SS, Nieuwdorp M, Blom B, Hazenberg MD (2020) Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients. Sci Transl Med 12 (556). https://doi.org/10.1126/scitranslmed.aaz8926

47.

Webb BJ, Brunner A, Ford CD, Gazdik MA, Petersen FB, Hoda D (2016) Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis 18(4):628–633. https://doi.org/10.1111/tid.12550CrossRefPubMed

48.

Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, de Groot P, de Vos WM, Högenauer C, Malfertheiner P, Mattila E, Milosavljević T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66(4):569–580. https://doi.org/10.1136/gutjnl-2016-313017CrossRefPubMed

49.

Shouval R, Youngster I, Geva M, Eshel A, Danylesko I, Shimoni A, Beider K, Fein JA, Sharon I, Koren O, Nagler A (2018) Repeated courses of orally administered fecal microbiota transplantation for the treatment of steroid resistant and steroid dependent intestinal acute graft vs. host disease: a pilot study (NCT 03214289). Blood 132(1):2121–2121. https://doi.org/10.1182/blood-2018-99-110270CrossRef

Titel: Non-viral pathogens of infectious diarrhoea post-allogeneic stem cell transplantation are associated with graft-versus-host disease
Publikationsdatum: 06.11.2023
Erschienen in: Annals of Hematology / Ausgabe 2/2024
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05526-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome–positive acute lymphoblastic leukemia: two-case report

Leukemic non-nodal cyclin D1- and SOX11-negative mantle cell lymphoma with CCND3::IGH rearrangement

Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine

Zanubrutinib-lenalidomide-rituximab (ZR2) in unfit diffuse large B-cell lymphoma: efficient and tolerant

Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia